Discovery of a DCAF11-dependent cyanoacrylamide-containing covalent degrader of BET-proteins

  • Bioorg Med Chem Lett. 2024 Jul 15:107:129779. doi: 10.1016/j.bmcl.2024.129779.
Gary Tin  1 Marko Cigler  2 Matthias Hinterndorfer  1 Kevin D Dong  3 Hana Imrichova  1 Steven P Gygi  3 Georg E Winter  4
Affiliations
  • 1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • 2. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. Electronic address: [email protected].
  • 3. Department of Cell Biology, Harvard Medical School, Boston, USA.
  • 4. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. Electronic address: [email protected].
Abstract

Targeted protein degradation is mediated by small molecules that induce or stabilize protein-protein interactions between targets and the ubiquitin-proteasome machinery. Currently, there remains a need to expand the repertoire of viable E3 Ligases available for hijacking. Notably, covalent chemistry has been employed to engage a handful of E3 Ligases, including DCAF11. Here, we disclose a covalent PROTAC that enables DCAF11-dependent degradation, featuring a cyanoacrylamide warhead. Our findings underscore DCAF11 as an interesting candidate with a capacity to accommodate diverse electrophilic chemistries compatible with targeted protein degradation.

Keywords
Cyanoacrylamide-based PROTACs; DCAF11; Targeted protein degradation.
Products